Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1470403 | 1.00 | KDM4E (0.49) | KDM4EABL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL1470405 | 1.00 | KDM4E (0.49) | KDM4EABL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL16196909 | 0.85 | KDM4E (0.48) | KDM4EABL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL1471145 | 0.84 | SMN1; SMN2 (0.48) | KDM4EABL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL6351809 | 0.84 | EIF2AK4 (0.52) | KDM4EABL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL1471341 | 0.84 | EIF2AK4 (0.52) | KDM4EABL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL1471343 | 0.84 | EIF2AK4 (0.52) | KDM4EABL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5318004 | 0.83 | KDM4E (0.49) | KDM4EABL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL27734362 | 0.82 | KDM4E (0.54) | KDM4EABL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL27734364 | 0.82 | KDM4E (0.54) | KDM4EABL1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | claimed |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-01-24 | — | — | US | claimed |
| EP-1771421-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2007-04-11 | — | — | EP | claimed |
| WO-2006010751-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-02-02 | — | — | WO | claimed |
| CN-115745971-B | PARP7 inhibitor and application thereof | 北京华森英诺生物科技有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-115745971-A | PARP7 inhibitor and application thereof | 重庆华森制药股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-3371164-B1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES INC (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-108349936-B | Compounds as muscarinic receptor 4 antagonists | 纽罗克里生物科学有限公司 | 2021-10-01 | — | — | CN | disclosed |
| EP-3371164-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-1805158-B1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017079641-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-05-11 | — | — | WO | disclosed |
| US-8247437-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-08-21 | — | — | US | disclosed |
| US-7494999-B2 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC (US) | 2009-02-24 | — | — | US | disclosed |
| US-20090029971-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-01-24 | — | — | US | disclosed |
| EP-1771421-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2007-04-11 | — | — | EP | disclosed |
| US-20060205736-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060167012-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006010751-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006010751-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167012-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | PPARG, PPARA, PPARD | KDM4E 3245/4885ABL1 4048/4885LMNA 2528/4885 |
| US-20090029971-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | KDM4E 3245/4885ABL1 4048/4885LMNA 2528/4885 |
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | KDM4E 2539/4885ABL1 4631/4885LMNA 1497/4885 |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | HCAR2, HNMT, HPGD | KDM4E 2486/4885ABL1 4615/4885LMNA 1655/4885 |
| US-20060205736-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | PPARG, PPARA, PPARD | KDM4E 3245/4885ABL1 4048/4885LMNA 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.